TERM ID="NYU_TERM_1" STRING="Meta-analyses" FREQUENCY=1 START=337 END=350 LEMMA="META-ANALYSIS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="Rituximab" FREQUENCY=1 START=248 END=257 LEMMA="RITUXIMAB" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_3" STRING="anti-staphylococcus strategies" FREQUENCY=1 START=156 END=186 LEMMA="ANTI-STAPHYLOCOCCUS STRATEGY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="dermatological therapy" FREQUENCY=1 START=14 END=36 LEMMA="DERMATOLOGICAL THERAPY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_5" STRING="good-quality" FREQUENCY=1 START=46 END=58 LEMMA="GOOD-QUALITY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_6" STRING="good-quality randomised trials" FREQUENCY=1 START=46 END=76 LEMMA="RANDOMISED TRIAL GOOD-QUALITY" LEMMA_FREQUENCY=1 HEAD_TERM="randomised trials" HEAD_LEMMA="RANDOMISED TRIAL"
TERM ID="NYU_TERM_7" STRING="isotretinoin" FREQUENCY=1 START=698 END=710 LEMMA="ISOTRETINOIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_8" STRING="omalizumab" FREQUENCY=1 START=262 END=272 LEMMA="OMALIZUMAB" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_9" STRING="randomised trials" FREQUENCY=1 START=59 END=76 LEMMA="RANDOMISED TRIAL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_10" STRING="retrospective cohort" FREQUENCY=1 START=658 END=678 LEMMA="RETROSPECTIVE COHORT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="solution" FREQUENCY=1 START=238 END=246 LEMMA="SOLUTION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_12" STRING="studying safety data" FREQUENCY=1 START=489 END=509 LEMMA="STUDYING SAFETY DATA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_13" STRING="suicidal risk" FREQUENCY=1 START=712 END=725 LEMMA="SUICIDAL RISK" LEMMA_FREQUENCY=1
